Profile of use and access to statins in patients with coronary arterial disease in an outpatient clinic of a teaching hospital

References

• Gaziano TA, Bitton A, Anand S, et al. Growing epidemic of coronary heart disease in low- and middle-income countries. Curr Probl Cardiol. 2010;35(2):72–115.
   PubMed Web of Science ®Google Scholar
• Ference BA, Yoo W, Alesh I, et al. Effect of long-term exposure to lower low-density lipoprotein cholesterol beginning early in life on the risk of coronary heart disease: a Mendelian randomization analysis. J Am Coll Cardiol. 2012;60(25):2631–2639.
   PubMed Web of Science ®Google Scholar
• Baigent C, Blackwell L, Emberson J, et al. Efficacy and safety of more intensive lowering of LDL cholesterol: ameta-analysis of data from 170 000 participants in 26 randomised trials. Lancet. 2010;376(9753):1670–1681.
   PubMed Web of Science ®Google Scholar
• Mills EJ, O’Regan C, Eyawo O, et al. Intensive statin therapy compared with moderate dosing for prevention of cardiovascular events: a meta-analysis of >40 000 patients. Eur Heart J. 2011;32(11):1409–1415.
   PubMed Web of Science ®Google Scholar
• Lu Y, Cheng Z, Zhao Y, et al. Efficacy and safety of long-term treatment with statins for coronary heart disease: a Bayesian network meta-analysis. Atherosclerosis. 2016;254:215–227.
   PubMed Web of Science ®Google Scholar
• Faludi AA, Izar MCO, Saraiva JFK, et al. Atualização da Diretriz Brasileira de Dislipidemias e Prevenção da Aterosclerose – 2017 [Update of the Brazilian dyslipidemia and atherosclerosis prevention directive – 2017]. Arq Bras Cardiol. 2017;109(2):1–76.
   Google Scholar
• Grundy SM, Stone NJ, Bailey AL, et al. 2018 AHA/ACC/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA guideline on the management of blood cholesterol. J Am Coll Cardiol. 2019;73(24):e285–e350.
   PubMed Web of Science ®Google Scholar
• Ministério da Saúde. Protocolo Clínico e Diretrizes Terapêuticas Dislipidemia: prevenção de eventos cardiovasculares e pancreatite [Clinical protocol and therapeutic guidelines dyslipidemia: prevention of cardiovascular events and pancreatitis]. 2019. p. 1–35.
   Google Scholar
• Secretária de Estado de Saúde de Minas Gerais [Internet]. Componente Especializado da Assistência Farmacêutica – CEAFMG. [cited 2020 Mar 01]. Available from: https://www.saude.mg.gov.br/obtermedicamentosceaf/
   Google Scholar
• Álvares J, Guerra Júnior AA, de Araújo VE, et al. Access to medicines by patients of the primary health care in the Brazilian Unified Health System. Rev Saude Publ. 2017;51(Suppl 2:20s):1–10.
   PubMedGoogle Scholar
• Malta DC, Szwarcwald CL. Population-based surveys and monitoring of noncommunicable diseases. Rev Saude Publ. 2017;51:1S–4S.
   PubMed Web of Science ®Google Scholar
• Cesar LA, Ferreira JF, Armaganijan D, et al. Diretriz de Doença Coronária Estável [Stable coronary disease guideline]. Arq Bras Cardiol. 2014; 103(Suppl.2):1–59.
   PubMedGoogle Scholar
• Sociedade Brasileira de Cardiologia [Internet]. Calculadora para estratificação de risco cardiovascular [Calculator for cardiovascular risk stratification]. [cited 2019 May 10]. Available from: http://departamentos.cardiol.br/sbc-da/2015/CALCULADORAER2017/index.html
   Google Scholar
• Ministério da Saúde. Relação Nacional de Medicamentos Essenciais: RENAME 2018. [National List of Essential Medicines]. 2018. p. 1–218.
   Google Scholar
• World Health Organization [Internet]. Anatomical therapeutic chemical. [cited 2019 May 10]. Available from: https://www.whocc.no/atc_ddd_index/
   Google Scholar
• Arnold SV, Kosiborod M, Tang F, et al. Patterns of statin initiation, intensification, and maximization among patients hospitalized with an acute myocardial infarction. Circulation. 2014;129(12):1303–1309.
   PubMed Web of Science ®Google Scholar
• Zhang L, Li J, Li X, et al. National assessment of statin therapy in patients hospitalized with acute myocardial infarction: Insight from China PEACE-Retrospective AMI study, 2001, 2006, 2011. PLoS One. 2016;11(4):e0150806.
   PubMed Web of Science ®Google Scholar
• Cheng-Lai A, Snead J, Ng C, et al. Comparison of adherence to the 2013 ACC/AHA cholesterol guideline in a teaching versus nonteaching outpatient clinic. Ann Pharmacother. 2018;52(4):338–344.
   PubMed Web of Science ®Google Scholar
• Murphy SA, Cannon CP, Blazing MA, et al. Reduction in total cardiovascular events with ezetimibe/simvastatin post-acute coronary syndrome: the IMPROVE-IT trial. J Am Coll Cardiol. 2016;67(4):353–361.
   PubMed Web of Science ®Google Scholar
• Ministério da Saúde. Comissão nacional de incorporação de tecnologias no Sistema Único de Saúde – CONITEC [Internet]. Ezetimiba no tratamento da dislipidemia [Ezetimibe in the treatment of dyslipidemia]. [cited 2019 May 10]. Available from: http://conitec.gov.br/
   Google Scholar
• Rodriguez F, Maron DJ, Knowles JW, el al. Association between intensity of statin therapy and mortality in patients with atherosclerotic cardiovascular disease. JAMA Cardiol. 2017;2(1):47–54.
   PubMed Web of Science ®Google Scholar
• Schonberger RB, Vallurupalli V, Matlin H, et al. Underuse of statins for secondary prevention of atherosclerotic cardiovascular disease events among ambulatory surgical patients. Prev Med Rep. 2020;18:101085.
   PubMedGoogle Scholar
• Chan J, Rajalingam T, Fossella J, et al. Vascular quality of care assessment: clinicians' adherence to lipid lowering therapy for patients with atherosclerotic cardiovascular disease. Ann Vasc Surg. 2020. DOI:10.1016/j.avsg.2020.06.003.
   Google Scholar
• Cicero AFG, Landolfo M, Ventura F, et al. Current pharmacotherapeutic options for primary dyslipidemia in adults. Expert Opin Pharmacother. 2019;20(10):1277–1288.
   PubMed Web of Science ®Google Scholar
• Ministério da Saúde. [Internet]. Programa Aqui Tem Farmácia Popular. [cited 2019 May 10]. Available from: http://www.saude.gov.br/acoes-e-programas/farmacia-popular/sobre-o-programa
   Google Scholar
• Nascimento R, Álvares J, Junior AAG, et al. Availability of essential medicines in primary health care of the Brazilian Unified Health System. Rev Saude Publ. 2017;51(Suppl 2:10s):1–12.
   PubMedGoogle Scholar
• Helfer AP, Camargo AL, Tavares NUL, et al. Affordability and availability of drugs for treatment of chronic diseases in the public health care system. Rev Panam Salud Publica. 2012;31(3):225–232.
   PubMed Web of Science ®Google Scholar
• Preiss D, Welsh P, Murphy S, et al. Risk of incident diabetes with intensive-dose compared with moderate-dose statin therapy: a meta-analysis. JAMA. 2011;305(24):2556–2564.
   PubMed Web of Science ®Google Scholar
• Nascimento RCM, Mueller T, Godman B, et al. Real-world evaluation of the impact of statin intensity on adherence and persistence to therapy: a Scottish population-based study. Br J Clin Pharmacol. 2020. DOI:10.1111/bcp.14333
   Web of Science ®Google Scholar
• Ford ES, Ajani UA, Croft JB, et al. Explaining the decrease in US deaths from coronary disease, 1980–2000. N Engl J Med. 2007;356(23):2388–2398.
   PubMed Web of Science ®Google Scholar
• Nascimento R, Guerra AA, Alvares J, et al. Statin use in Brazil: findings and implications. Curr Med Res Opin. 2018;34(10):1809–1817.
   PubMed Web of Science ®Google Scholar
• Cadogan CA, Ryan C, Hughes CM. Appropriate polypharmacy and medicine safety: when many is not too many. Drug Saf. 2016;39(2):109–116.
   PubMed Web of Science ®Google Scholar